ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The cell-free biomanufacturing start-up EnginZyme has raised $22 million in series B financing from Bunge Ventures, Sofinnova Partners, and others. The Swedish company aims to replace petrochemical production of plastics, rubber, and other materials with a process that uses enzymes and packed-bed reactors. EnginZyme claims that its process is cheaper and easier to scale up than other biomanufacturing methods. It plans to use the funding to improve the scalability of its technology.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter